argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

argenx announced a tender offer to acquire Forte Biosciences for $77 per share in cash. The acquisition adds Forte's first-in-class anti-CD122 monoclonal antibody FB102 to argenx's immunology pipeline. The tender offer commenced on August 6, 2026, with an expiration date of August 26, 2026, and is not subject to a financing condition. Forte's Board of Directors has recommended stockholders accept the offer.

argenx will host a webinar on June 23, 2026, to discuss advancing FcRn leadership into autoimmune myositis. The company will present data on efgartigimod showing sustained patient benefits in myositis and Sjogren's disease, with management and external key opinion leaders from leading medical institutions participating.

Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.

argenx announced that its management team will participate in two major investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference on June 3 in Chicago and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami. Live webcasts will be available on the company's investor website.

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

The FDA approved a label expansion for Argenx's VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo to treat all serotypes of adult patients with generalized myasthenia gravis (gMG), including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients. The approval expands the addressable market by 18% and positions the franchise to exceed $5 billion in annual sales with 64% year-over-year growth. ARGX shares rose 2.33% following the announcement.

The FDA has expanded approval of VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) to treat all serotypes of adult patients with generalized myasthenia gravis, including seronegative patients who previously had limited treatment options. The approval is based on the Phase 3 ADAPT SERON study, which demonstrated clinically meaningful improvements in patient daily living activities with a consistent safety profile.

argenx, a global immunology company, announced it will host a conference call on May 7, 2026 at 2:30 PM CET to discuss its first quarter 2026 financial results and provide a business update. The company is committed to developing novel antibody-based medicines for severe autoimmune diseases.

argenx announced positive Phase 3 trial results for VYVGART across multiple myasthenia gravis (MG) subtypes and chronic inflammatory demyelinating polyneuropathy (CIDP) at the 2026 AAN Annual Meeting. ADAPT OCULUS demonstrated VYVGART as the first targeted biologic treatment for ocular MG, while ADAPT SERON showed efficacy across seronegative MG patients. ADHERE analysis supported earlier use of VYVGART Hytrulo in treatment-naïve CIDP patients with 87.5% achieving early benefit. The company also presented Phase 3 trial designs for empasiprubart in CIDP and follow-up data for adimanebart in congenital myasthenic syndromes.

Folia Health announced a collaboration with argenx to launch a first-of-its-kind at-home observational real-world evidence initiative for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study uses Folia's home-reported outcomes platform to capture symptom severity, treatment utilization, and daily disease management directly from patients and caregivers over a six-month period.

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.